title: [Statins diabetogenicity: are all the same? state of art].
abstract: Statins are the cornerstone of cardiovascular prevention for general population, and in patients with type 2 diabetes mellitus (T2DM). However, statin therapy predisposes to type 2 diabetes, particularly in patients with predisposition to this condition. Some statins have been associated with increases in blood glucose in patients with or without DM2, and others have shown to have neutral effects, varying from one another their glucose or diabetogenic capacity. In many statin trials the incidence of DM2 has not been systematically evaluated and others the power to detect differences between statins is lacking. Evidence highest quality available comes from the meta-analysis of controlled clinical trials. The only controlled clinical trial to evaluate the incidence of new-onset T2DM is the J-PREDICT conducted with pitavastatin in patients with abnormal glucose tolerance. Preliminary results of this study show that pitavastatin is associated with a significant decrease in the incidence of de novo T2DM compared to only modification lifestyle. Therefore, pitavastatin may be an appropriate therapeutic alternative of choice to reduce vascular risk in patients with T2DM or at risk of presenting it.
authors.affiliation: Medical Affairs Cardiovascular Area, ESTEVE, Barcelona, España. Electronic address: 29815jrt@gmail.com.
authors.forename: Joan
authors.initials: J
authors.lastname: Rius Tarruella
authors.affiliation: Unidad de Riesgo Cardiovascular y Lípidos, Servicio de Medicina Interna, Hospital General Universitario Gregorio Marañón, Madrid, España.
authors.forename: Jesús
authors.initials: J
authors.lastname: Millán Núñez-Cortés
authors.affiliation: Unidad de Riesgo Cardiovascular y Lípidos, Servicio de Endocrinología y Nutrición, Hospital del Mar, Barcelona, España.
authors.forename: Juan
authors.initials: J
authors.lastname: Pedro-Botet
authors.affiliation: Unidad de Riesgo Cardiovascular y Lípidos, Servicio de Medicina Interna, Hospital Universitario de Bellvitge, Barcelona, España.
authors.forename: Xavier
authors.initials: X
authors.lastname: Pintó Sala
mesh_terms: D001786:Blood Glucose / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000453:epidemiology* / Q000517:prevention & control; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015994:Incidence
chemical_list: D001786:Blood Glucose; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Cardiovascular disease; Diabetes mellitus tipo 2; Disglicemia; Dysglycemia; Enfermedad cardiovascular; Estatinas; HbA1c; Prevención; Prevention; Statins; Type 2 diabetes mellitus